|
|
|
|
|
|
|
|
|
Webinar: Beyond the Starting Material: Building a Path to GMP Manufacturing Success
|
Cell therapy manufacturing success starts long before the GMP cleanroom. Join experts from New York Blood Center Enterprises’ Comprehensive Cell Solutions (CCS) team to explore how starting material sourcing, collection strategies, process development, and technology transfer shape manufacturing outcomes. Gain practical insights for reducing variability, strengthening process robustness, and preparing cell therapy programs for clinical and commercial manufacturing. Click here to learn more.
|
|
|
|
|
|
|
|
By Bernardo Estupiñán, Drug Biologics Consulting LLC
|
In recent years, digital platforms have emerged to help pharma/biotech companies discover, evaluate, and connect with CDMOs more efficiently. These resources have different functions and limitations.
|
|
|
|
|
|
|
|
|
|
|
|
Capital Constraints In CDMO & Pharma M&A
|
|
Q&A | Vector BioMed
|
Capital constraints are reshaping CDMO and pharma strategies, driving selective M&A, prioritizing partnerships, and enforcing financial discipline amid tighter investment conditions.
|
|
|
|
|
|
A New Player With A Long History
|
|
Datasheet | Andelyn Biosciences
|
Leveraging more than 15 years in the field, Andelyn Biosciences provides custom development and manufacturing of AAV vectors for gene therapy as a full-service concept-to-commercialization cGMP CDMO.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Connect With Cell & Gene: |
|
|
|
|
